News

PAH market narrows
Enlarge image

PharmaSwitzerlandGermany

PAH market narrows

24.10.2012 - The competition for PAH treatments will become fierce. Actelion and Bayer both plan to market new treatments for this rare disease.

Good news for PAH (pulmonal arterial hypertension) patients: two new drugs are planned for market release. The Swiss biotech Actelion submitted a new drug application to the FDA for its Opsumit macitentan treatment. The filing is based on data from a Phase III study, which proved to be able to reduce the risk of a morbidity or mortality event compared to placebo. A low-dose of Opsumit reduced the risk by 30%, while the high dose had a 45% reduction. The compound is a tissue-targeting endothelin receptor antagonist and is thought to replace revenues from Tracleer, Actelion’s best-seller which will lose patent protection in 2015.

At the same time as Actelion announced the application, German pharma Bayer AG announced that its compound riociguat met the primary endpoint in a Phase III study. The oral soluble guanylyl cyclase (sGC) stimulator led to an improvement in a six minute walk test enhancing the patient’s walk distance to 36 meters. Bayer plans to submit regulatory filing for riociguat in the first half next year. Analysts said that macitentan might become the next first-line treatment and expected high revenues. Riociguat however might become a second line option and get additional competition from Pfizer’s Sildenafil, which is already approved for PAH and acts via the same pathway.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/pah-market-narrows.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SARTORIUS128.00 EUR3.85%
  • CO.DON2.29 EUR3.15%
  • WILEX3.03 EUR2.71%

FLOP

  • SANTHERA96.50 CHF-3.40%
  • PAION2.03 EUR-2.87%
  • ADDEX3.16 CHF-2.47%

TOP

  • WILEX3.03 EUR52.3%
  • SARTORIUS128.00 EUR17.9%
  • FORMYCON16.15 EUR16.2%

FLOP

  • ADDEX3.16 CHF-8.1%
  • SANTHERA96.50 CHF-6.3%
  • BIOFRONTERA1.90 EUR-5.9%

TOP

  • SANTHERA96.50 CHF2387.1%
  • WILEX3.03 EUR413.6%
  • FORMYCON16.15 EUR99.9%

FLOP

  • CYTOS0.33 CHF-89.0%
  • MOLOGEN5.65 EUR-53.5%
  • PAION2.03 EUR-53.0%

No liability assumed, Date: 26.02.2015